Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Hematology Block 2 > Myelo- Syndromes > Flashcards

Myelo- Syndromes Flashcards

1
Q

Key myeloproliferative syndromes include:

A

Polycythemia vera

Essential Thrombocytosis

Myelofibrosis

CML

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Erythrocytosis:

A

An increase in the number of circulating RBCs per volume of blood.

Synonym: polycythemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is hyperviscosity syndrome, and what symptoms are associated with it?

A
  • Some pts with erythrocytosis (from whatever cause) develop this syndrome.
  • Erythrocytosis with hyperviscosity symptoms should be treated with phlebotomy.
  • Symptoms include:
  • Headaches
  • Visual changes
  • Tinnitus
  • Dizziness
  • Paresthesias
  • Decreased mental acuity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Secondary erythrocytosis:

A

These conditions tend to lead to erythrocytosis because tissue hypoxia induces erythropoietin (epo) production by the kidney.

Other less common causes of increased erythropoietin levels include liver or kidney tumors which secrete erythropoietin, rare genetic disorders (eg a familial mutation in the epo receptor, making it constitutively active), and drug treatment with either androgens or erythropoietin.

Here, there is not a risk of blood clots, since the blood is being produced by a normal stimulus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Erythrocytosis due to appropriate increases in EPO:

A

(These all include tissue hypoxia)

  • Life at high altitude
  • High affinity hemoglobins
  • Cardiopulmonary disease leading to hypoxia
  • Obesity-Hypoventilation syndrome

•Obstructive sleep apnea

•High carboxyhemoglobin levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Myeloproliferative disorders are _____ disorders leading to autonomous production of hematopoietic cells from ____ lineages.

A

Myeloproliferative disorders are stem cell disorders leading to autonomous production of hematopoietic cells from all three lineages. (red cells, white cells, platelets)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

All of the myeloproliferative disorders are ____

A

clonal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is Polycythemia vera?

A
  • Definition: A neoplastic disorder arising from a pluripotent stem cell, generally characterized by erythrocytosis, with or without thrombocytosis and leukocytosis.
  • Incidence 10 new cases per million
  • Highest incidence in ages 50-75, but 5% occur in pts <40 y.o.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

•The erythroid progenitor cells of patients with P. vera, are capable of growing and dividing in the absence of _____

A

erythropoietin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How is P vera diagnosed?

A

•Low or undetectable erythropoietin level

•JAK2 mutation

  • JAK 2 is a tyrosine kinase which functions immediately downstream of the growth factor receptors. It is activated once the growth factor receptor gets turned on.
  • In 2005, investigators found a mutation JAK2 V617F, which causes loss of auto-inhibition, leading to constitutive activation of JAK2, thus causing unregulated signaling thru growth factor receptors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

JAK2 V617F

A

JAK2 V617F has been found in

  • 99% of P vera
  • 60-65% of ET and myelofibrosis
  • Some people with MDS and acute leukemia
  • No normal patients

•Next steps:

  • Determine causality and clinical implications
  • Find effective inhibitors of JAK2
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe the progression of P vera if untreated:

A

•Latent phase - asymptomatic

•Proliferative phase - pts may be hypermetabolic or have sx of hyperviscosity or thrombosis

•Spent phase - anemia, leukopenia, secondary myelofibrosis, increasing liver and spleen size, fevers, weight loss

•Secondary AML

  • 1-2% of pts treated with phlebotomy alone
  • Certain drug therapies increase risk
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Symptoms associated with P vera

A

•Symptoms common to all erythrocytosis:

  • Headache, decreased mental acuity, weakness

•Sx more specific to P vera and myeloproliferative diseases.

  • Pruritis after bathing (super itchy)
  • Erythromelalgia (palms/soles of hands and feet burning)
  • Hypermetabolic symptoms
  • Thrombosis (arterial or venous)
  • Budd-Chiari syndrome (thrombosis of the hepatic vein) is associated with P vera and other MPNs (It’s also associated with PNH)
  • Hemorrhage
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Physical exam findings in patients with P vera

A

•Facial plethora (fullness and redness in the face)

•Splenomegaly (gets worse with time)

  • found in 70% of pts

•Hepatomegaly

  • 40% of pts

•Distension of retinal veins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

P. vera lab findings:

A

•CBC:

  • ­elevated Hgb/Hct
  • ­elevated WBC in 45%
  • ­elevated Plts (in 65% of patients)
  • Basophilia (can be seen in all MPDs)

•­Elevated uric acid (can lead to gout) and B12

•Low EPO levels

•Positive JAK2 V617F

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

P vera treatment:

A

•Phlebotomy

•Myelosuppressive agents:

  • Hydroxyurea
  • Alkylating agents such as busulfan
  • 32P

•Interferon alpha

•Low dose aspirin has been found to decrease the risk of thrombosis in PV, and should be given to almost all patients

17
Q

Pros/cons of P vera treatment with phlebotomy:

A

•Generally, the best initial treatment for P vera

  • No increase in progression to AML
  • Rapid onset
  • No marrow suppression
  • Remove 500 cc blood 1-2x/wk to target Hct 45%, then maintain
  • Downsides:
  • Increased risk of thrombosis
  • No effect on progression to spent phase
  • May be insufficient to control disease
18
Q

Essential Thrombocytosis:

A
  • Incidence is similar to P vera
  • 20% of pts are <40 y.o.
  • Exact pathophysiology is unclear
  • 90% have a somatically acquired driver mutation in either JAK2, CALR, or MPL
    • •JAK2 V617F
    • •CALR (calreticulin)—mutated protein will activate MPL
    • •MPL—the thrombopoietin receptor—when mutated, is constitutively active
19
Q

How is ET diagnosed?

A

•First, rule out secondary causes of thrombocytosis:

  • cancer
  • Infection
  • inflammation
  • bleeding
  • iron deficiency
  • Platelet count should be >450 on 2 separate occasions, at least 1 month apart
  • Exclude CML by absence of Philadelphia chromosome
  • JAK2 is positive 60-65% of the time
  • Abnormal bone marrow biopsy
20
Q

Complications of ET:

A
  • Rarely progresses to AML (progression in <1% of pts)
  • May progress to secondary myelofibrosis
  • Major complication is thrombosis
  • Occurs in 20-30% of patients
  • Clots may be arterial or venous
21
Q

Symtoms of ET:

A
  • Many patients are asymptomatic at time of diagnosis
  • Digital ischemia from microvascular thrombi
  • Erythromelalgia
  • Pruritis
  • Hemorrhage - seen in 40% of pts
22
Q

Lab findings with ET:

A
  • Iron studies should be normal, as should the sedimentation rate, which is a measure of inflammation.
  • Platelets can be very large and bizarrely shaped
  • Marrow shows clusters of abnormal megakaryocytes.
  • 60-65% may have JAK2 mutation
  • CALR or MPL may be mutated
23
Q

ET treatment:

A
  • Use hydroxyurea, anagrelide, or interferon alpha
  • Treatment targeted at reducing the platelet count.
  • Whom to treat is controversial.
  • In general, treat those who have had or are at risk for thrombosis, those >65 y.o
  • Why treat?
  • In pts at risk for thrombosis, Rx reduces risk of thrombosis and maybe secondary myelofibrosis.
24
Q

Myelofibrosis is a ____ disorder affecting ____

A

Clonal stem cell disorder affecting megakaryocytes predominantly

25
Q

All myeloproliferative disorders can result in a ___ phase which can be difficult to distinguish from primary ___

A

All myeloproliferative disorders can result in a spent phase which can be difficult to distinguish from primary MF

26
Q

Myelofibrosis patient outcome

A

•Natural History

  • Median survival is 5 yrs
  • Transforms into AML in 5-20%

•Symptoms

  • >50% pts present with sx of anemia and thrombocytopenia
  • Pts may have fever, sweats, wt loss
  • As spleen enlarges (from EMH), pts may have abdominal pain, early satiety.
27
Q

Myelofibrosis physical findings:

A

Massive splenomegaly

Hepatomegaly

28
Q

Myelofibrosis lab findings:

A
  • Early on, pts may have high­ platelets and normal Hgb and WBC.
  • Anemia, and low Plts and low WBC seen as disease progresses
  • Peripheral smear shows leukoerythroblastic picture, with teardrops, NRBC and early granulocytes
  • “Dry tap” or inability to aspirate liquid marrow frequently seen
  • Increased collagen and reticulin fibrosis on bone marrow biopsy
29
Q

What is shown in this smear?

A

This is a leukoerythroblastic smear

(seen in patients with myelofibrosis)

30
Q

What is shown in this image?

A

This is a reticulin stain, which shows a ton of black-staining reticulin fibers.

This is a patient with myelofibrosis.

31
Q

What is the treatment for myelofibrosis?

A
  • There is no definitive therapy
  • If patient is young, BM transplant can be done, but older patients have too high mortality
  • Rx is supportive, with transfusions
  • Splenectomy can be done for sx of abdominal pain, but frequent complications of thrombosis, hemorrhage, and infection.
32
Q

A 65 y/o man presents with a platelet count of 600. What are his possible diagnoses?

A

P vera

Essential Thrombocytosis

Iron deficiency

Rheumatoid arthritis

33
Q

What are myelodysplastic syndromes?

A
  • Definition: Conditions in which there is disordered maturation in 1 or more cell lines, usually producing cytopenias
  • Population of dysplastic cells represent an abnormal clone of cells. With time, the clone can remain stable or progress, generating further clones with worsening cytopenias and further cytogenetic abnormalities
34
Q

Myelodysplastic syndrome clinical features:

A

•This is a disease of the elderly.
In pts older than 60, incidence is 1 in 1500

•Some pts are diagnosed because of abnormal CBC findings (low counts). Some present because of symptomatic anemia or thrombocytopenia.

35
Q

What are the lab findings in a patient with myelodysplastic features?

A
  • Any cell line or combination of cell lines can be affected.
  • Peripheral cell abnormalities
  • Macrocytosis of RBCs (with a normal B12/folate)
  • Neutrophils can be hypogranular or bi-lobed.
  • Can have monocytosis
36
Q

What are the findings of a bone marrow biopsy in a patient with myelodysplastic syndrome?

A

•Megaloblastic erythropoeisis

•Ringed sideroblasts

•Abnormal nucleus of RBC precursors (dyserythropoiesis)

•Small megakaryocytes with abnormally hypolobated nuclei

•Blast cells should account for <20% of marrow cells (if above 20%, is considered AML)

37
Q

What cytogenic abnormalities are associated with MDS?

A
  • Monosomy 5, 7, or 8 can be seen
  • Deletion of the long arm of 5 is associated with a better prognosis
  • Complex cytogenetics (many many abnormalities) has a very bad prognosis
38
Q

Treatment/prognosis of patients with MDS:

A

•Treatment is usually supportive

•Transfusions of RBCs and platelets as necessary

•Growth factors (epo and G-CSF) can help with some of the cytopenias

  • Thalidomide and derivatives may help relieve some transfusion dependence in a subset of pts.
  • Certain agents which cause DNA hypomethylation can lead to remission.

•Once the patient develops AML, the chances of achieving remission are decreased, and the duration of any remission is much shorter.

Hematology Block 2 (7 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions